Skip to main content
Category

Article

Summer Travel 2022 – We’re Still in a Pandemic

     

In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups and downs.

Another COVID-19 Wave Kicks Off

Now in the third year of the COVID-19 pandemic, while it seemed that SARS-CoV-2 was moving toward endemicity, infections in the United States are again rising.1

One thing we do know about SARS-CoV-2 is that it is constantly changing. Although new variants are an expected part of the evolution of viruses, monitoring each one that surfaces is essential in ensuring we are prepared. This is especially true if a new variant is more aggressive, highly transmissible, vaccine-resistant, or able to cause more severe disease when compared with the original strain of the virus.2

COVID-19 Isn’t Quite Finished

There’s still a lot to learn about COVID-19, Omicron (BA.1) and its subvariants.

In February 2022, two new Omicron subvariants, BA.4 and BA.5, that originated in South Africa3 were classified by the European Centre for Disease Prevention and Control and the World Health Organization as variants of concern.3 As of July 2, 2022, BA.4 and BA.5 are estimated to make up a combined 70% of the coronavirus variants in the United States.2

Travelling During the COVID-19 Pandemic

If you choose to travel this summer, it’s best to plan ahead and take precautions to protect yourself and others against COVID-19.4 Travelers are reminded to follow the Centers for Disease Control and Prevention (CDC) travel guidance as well as local and state advisories regarding COVID-19.

Take Precautions to Protect Yourself from COVID-19

COVID-19 vaccinations remain the most effective tool in preventing severe illness, hospitalization, and death from COVID-19.5 But even if you’re vaccinated, it’s still a good idea to take precautions to protect yourself, family members, children and others while traveling during the COVID-19 pandemic.6

Effective June 18, 2022, the CDC endorsed a recommendation that all children 6 months through 5 years of age should receive a COVID-19 vaccine. Parents and caregivers can now get their children at least 6 months of age vaccinated with the Pfizer-BioNTech or Moderna vaccines to better protect them from COVID-19. According to the CDC, all children, including children who have already had COVID-19, should get vaccinated.7

The CDC recommends not to travel if you have COVID-19 symptoms, tested positive for COVID-19, are waiting for results of a COVID-19 test, had close contact with a person with COVID-19, or are recommended to quarantine.8 Travelers are reminded to follow CDC COVID-19 travel guidance if they have COVID-19 symptoms, are waiting for test results, or have been in contact with someone with COVID-19.

Testing and Treatment for SARS-COV-2 Infection

We must continue to protect ourselves from COVID-19 and use the tools that we have at our disposal to respond to this ongoing pandemic. If you or anyone feels unwell or exhibits any signs of COVID-19, it’s best to contact a healthcare provider right away to test and seek treatment for COVID-19. 12

Test to Treat

COVID-19 medications are now available through your doctor, local pharmacies, and health clinics.

The Test to Treat program gives people a fast and easy way to get lifesaving treatment for COVID-19. Adults and children of all ages can be tested at a site. People 12 years and older who weigh more than 88 pounds (40 kg) and have high-risk conditions may be eligible for treatment.13

On July 6, 2022, the FDA revised the Emergency Use Authorization for Pfizer’s PaxlovidTM, allowing state-licensed pharmacists to prescribe the antiviral treatment directly to eligible patients with certain limitations.21. The FDA also determined that Merck’s LagevrioTM should only be prescribed by healthcare prescribers, and not by pharmacists.22

If you test positive for COVID-19, you should first consider seeking care from your primary health care provider or through a one-stop Test to Treat site available nationwide at hundreds of pharmacy-based clinics and Health Resources and Services Administration supported federally qualified health centers.14

The Test to Treat program does not change existing requirements for qualified healthcare providers to write the prescriptions for these medications. People can continue to get tested and treated by their own healthcare providers, who can prescribe these medications to eligible patients. Patients can pick up those prescriptions wherever oral antivirals are distributed.15

If these medications are inappropriate for patients, additional COVID-19 drug options outside the Test to Treat program are available. The National Institutes of Health (NIH) has developed and regularly updates Treatment Guidelines to help guide healthcare providers caring for patients with COVID-19.16

Point of Care Molecular Testing

While there are many different types of tests that have emergency use authorization (EUA) in the United States, molecular diagnostics/nucleic acid amplification tests (NAAT), remain the gold standard for identifying SARS-CoV-2 infection.17

Talis OneTM: The Next Big Thing in COVID-19 Molecular Testing

At Talis, we believe that accurate POC molecular tests that can provide results in minutes instead of hours are needed to meet the need for fast, accurate testing. But not all POC NAATs deliver the same accuracy and sensitivity that central lab NAATs deliver18, which is why we developed the Talis One COVID-19 Test System for use under Emergency Use Authorization (EUA), to deliver central lab quality NAAT results quickly and in a variety of care environments.20

For Air Travellers to the U.S.A.

Effective as of June 10, 2022, the CDC will no longer require air passengers traveling from a foreign country to the United States to show a negative COVID-19 test result or documentation of recovery from COVID-19 before they board their flight. The CDC will re-evaluate this decision in 90 days and could reinstate the requirement for pre-departure testing if there are new concerns about another variant.9

As a reminder, the CDC still requires proof of COVID-19 vaccination for non-U.S. citizen, non-immigrant air passengers arriving from a foreign country to the United States by air.9

For Land Travel to the U.S.A.

Effective as of April 21, 2022, the Department of Homeland Security (DHS) extended requirements to non-U.S. travelers entering the United States via land ports of entry and ferry terminals at the U.S. Mexico and U.S. Canada borders to be fully vaccinated against COVID-19 and provide related proof of vaccination upon request. These requirements will continue to apply to non-U.S. travelers who are traveling both for essential and non-essential reasons, and do not apply to U.S. citizens, Lawful Permanent Residents, or U.S. nationals.10

Domestic Travel During COVID-19

If you plan to stay close to home, make sure you are up to date with your COVID-19 vaccines before travel and make sure you are aware of any travel restrictions in place at the state and local level.11

     

Related Articles

Article
July 18, 2022

Summer Travel 2022 – We’re Still in a Pandemic

In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
Article
June 15, 2022

Sexually Transmitted Infections and Disease: the Silent Pandemic

Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
Article
May 13, 2022

COVID-19: It’s Not Over Yet

It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
Article
March 16, 2022

COVID-19 Testing for Travel—What Your Patients Need to Know

Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

Join Our Newsletter

Subscribe to our newsletter for information about our products and company updates.


    TALIS BIOMEDICAL

    The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

    © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

    *Additional testing solutions are currently in development and not available for sale.

    References

    1. COVID-19 in 2022—The Beginning of the End or the End of the Beginning? JAMA. Published online May 27, 2022. doi:10.1001/jama.2022.9655. https://pubmed.ncbi.nlm.nih.gov/35622357/. Carlos del Rio, MD1,2; Preeti N. Malani, MD, MSJ3,4
    2. Omicron, Delta, Alpha, and More: What To Know About the Coronavirus Variants. Originally published: Dec. 10, 2021. Updated: July 5, 2022. https://www.yalemedicine.org/news/covid-19-variants-of-concern-omicron. https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
    3. European Centre for Disease Prevention and Control. Epidemiological update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA.5. 13 May 2022. https://www.ecdc.europa.eu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba5.
    4. COVID-19 Travel Recommendations. https://wwwnc.cdc.gov/travel/noticescovid19.
    5. Why to Get a COVID-19 Vaccine. https://www.cdc.gov/media/releases/2022/s0318-COVID-19-vaccines-protect.html
    6. Benefits of Getting A COVID-19 Vaccine. Updated June 19, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html
    7. CDC Recommends COVID-19 Vaccines for Young Children. https://www.cdc.gov/media/releases/2022/s0618-children-vaccine.html
    8. Travel. Updated June 13, 2022. https://www.cdc.gov/coronavirus/2019-ncov/travelers/index.html#:~:text=You%20have%20COVID%2D19%20symptoms,if%20you%20had%20no%20symptoms.
    9. CDC Travel. Updated June 13, 2022. https://www.cdc.gov/coronavirus/2019-ncov/travelers.
    10. CDC Travel; International. Updated June 13, 2022. https://www.cdc.gov/coronavirus/2019-ncov/travelers/international-travel-during-covid19.html.
    11. DHS Extends COVID-19 Vaccination Requirements for Non-U.S. Travelers Entering the United States via Land Ports of Entry and Ferry Terminals. April 21, 2022. https://www.dhs.gov/news/2022/04/21/dhs-extends-covid-19-vaccination-requirements-non-us-travelers-entering-united.
    12. CDC-Public Health Professionals Gateway-Health Department Directories State & Territorial Health Department Websites. https://www.cdc.gov/publichealthgateway/healthdirectories/healthdepartments.html.
    13. CDC COVID-19. If You Are Sick or Caring for Someone. Updated Feb. 9, 2022. https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/index.html.
    14. FDA Updates on Paxlovid for Health Care Providers. Content current as of 05/04/2022. https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers.
    15. Office of the Assistant Secretary for Preparedness and Response (ASPR). https://aspr.hhs.gov/TestToTreat/Documents/Fact-Sheet.pdf.
    16. New COVID-19 Test to Treat Initiative and Locator Tool. https://emergency.cdc.gov/newsletters/coca/040422.htm.
    17. NIH COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/guidelines-development/.
    18. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Published. 2021 Jan 22. https://pubmed.ncbi.nlm.nih.gov/33480973/. Hanson KE, Caliendo AM, Arias CA, et al.
    19. Diagnostics for SARS-CoV-2 infections. Nat Mater. Published 2021;20(5):593-605. https://pubmed.ncbi.nlm.nih.gov/33589798/. Kevadiya BD, Machhi J, Herskovitz J, et al.
    20. Evaluation of the Talis One™ Covid-19 Test System for the Rapid Detection of Sars-Cov-2 and Emerging Variants. Talis Whitepaper Fall 2021.
    21. Coronavirus (COVID-19) Update: FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations.
    22. FDA is letting pharmacists prescribe Pfizer’s Paxlovid but won’t do the same for Merck’s Lagevrio. https://www.fiercepharma.com/pharma/fda-letting-pharmacists-prescribe-pfizers-paxlovid-wont-do-same-mercks-lagevrio#:~:text=%E2%80%9CThe%20FDA%20has%20determined%20that,for%20provider%2Dpatient%20consultation.%E2%80%9D

    Sexually Transmitted Infections and Disease: the Silent Pandemic

         

    Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United States, and that the scope, impact, and consequences of STDs are under recognized by the public and in healthcare.”1

    Today, the United States is in the midst of a major sexually transmitted diseases (STDs) epidemic and public health crisis. Over the past decade, current recorded rates of STDs are at an all-time high2 with alarming increases in rates of sexually transmitted infections (STIs) of chlamydia, gonorrhea, and syphilis.

    A Pressing Public Health Challenge

    STDs are preventable—and infections are treatable. Many Americans largely underestimate the risk of STIs and for myriad reasons may not proactively seek care. Without diagnosis, testing, and treatment, the long-term health consequences of STDs are significant. The social stigma associated with STDs continues to complicate STD diagnosis, prevention, and treatment efforts, while access to care and social equity often factor in to approaches to reach groups at higher risk for contracting STDs.2

    Today, the STD epidemic still remains a critical public health challenge3 that disproportionately affects certain racial, ethnic, geographic, and socioeconomic groups. Such disparities in STD rates are complex to understand but may be rooted in a number of social factors such as poverty, unemployment, inadequate access to health care, lack of education, discrimination, social inequality, and cultural influences.4 While substantial progress has been made in preventing, diagnosing, and treating certain STDs in recent years, approximately 20 million new STI infections occur in the United States each year, with half of them occurring in adolescents and young adults ages 15–24.5

    What We Know About Sexually Transmitted Infections and Diseases

    STIs refer to a pathogen e.g., virus, bacteria, fungus, or parasite, that usually passes from one person to another through sexual contact, whereas the term STD refers to a recognizable disease state that has developed from an STI infection.6

    More than 30 different bacteria, viruses and parasites are known to be transmitted through sexual contact. Eight of these pathogens are linked to the greatest incidence of sexually transmitted disease. Of these, 4 are currently curable: chlamydia, gonorrhea, syphilis and trichomoniasis. The other 4 are viral infections which are incurable: hepatitis B, herpes simplex virus (HSV or herpes), HIV and human papillomavirus (HPV).7

    Reported Cases

    In 2019, U.S. health departments reported that cases of chlamydia, gonorrhea, and syphilis have increased for the sixth consecutive year – reaching a new, all-time high.8

    • 1.8 million cases of chlamydia, an increase of nearly 20 percent since 2015.
    • 616,392 cases of gonorrhea, an increase of more than 50 percent since 2015; and
    • 129,813 cases of syphilis (all stages), an increase of more than 70 percent since 2015.

    STDs During COVID-19

    Reported cases of STDs in the US decreased during the early months of the COVID-19 pandemic, but most had resurged by the end of 2020, with 2.4 million cases of STDs reported.Ultimately, reported cases of gonorrhea, syphilis, and congenital syphilis surpassed 2019 levels, while chlamydia declined.9

    In 2020,

    • 1,579,885 cases of chlamydia were reported to the CDC, making it the most common notifiable sexually transmitted infection in the United States for this year.9
    • 677,769 cases of gonorrhea were reported to the CDC, making it the second most common notifiable sexually transmitted infection in the United States for this year.9
    • Between 2019–2020, reported gonorrhea rates increased among both males and females in most racial/Hispanic ethnicity groups, with the greatest increases observed among non-Hispanic Black/African American persons and non-Hispanic persons of multiple races.9

    Social Determinants of Health: Know What Affects Health

    Social Determinants of Health (SDOH) are social and economic conditions such as poverty, stigma, housing, food insecurity, discrimination, racism, medical mistrust, violence/trauma, access to care, and education, that are considered the underlying, contributing factors of health inequities. Addressing these SDOH is a primary approach to help (a) achieve health equity, so everyone has the opportunity to attain their full health potential, and (b) prevent the disadvantages due to social position or other socially determined circumstance”.10

    What is Health Equity

    Health equity is achieved when everyone has an equal chance to be healthy regardless of their background race, ethnicity, income, gender, religion, sexual identity, and disability. Research shows that there are higher rates of STDs among some racial or ethnic minority groups compared to whites. It is important to understand that these higher rates are not caused by ethnicity or heritage, but by social conditions that are more likely to affect minority groups. Factors such as poverty, large gaps between the rich and the poor, fewer jobs, and low education levels can make it more difficult for people to stay sexually healthy.11

    Health Inequities and Disparities

    Social inequity often leads to health inequity and, ultimately, manifests as health disparities.12 It is important to recognize the negative impact that health disparities and inequities has that adversely impacts certain racial, ethnic, geographic, and socioeconomic groups access to receive quality healthcare, including STI testing, prevention, and treatment.13

    Testing Solutions to Ensure Healthcare Equity

    Numerous factors contribute to the persistent STI public health burden, but of particular importance is delay in treatment resulting from lengthy diagnostic protocols.14 Point-of-care (POC) tests offer many advantages regarding early diagnosis, detection, chronic disease screening, and infectious disease management as an important strategy to address the STIs in the United States. While access to care and confidentiality are major barriers to STI care, POC tests allow the clinician to provide patients with immediate and confidential test results, diagnosis, and treatment during the same appointment.15

    Tests for Chlamydia and Ghonorrhea

    The goal of screening sexually active adolescents and adults (including pregnant women), who are asymptomatic for chlamydia or gonorrhea, is to catch and treat infections that may present without symptoms, to prevent additional transmission and complications.16

    A Clear Need for Rapid Chlamydia and Ghonorrhea Tests

    Nucleic acid amplification tests (NAATs) are considered the gold standard for screening chlamydia and gonorrhea infections because their sensitivity and specificity are high for detecting these infections.17

    Most NAATs for chlamydia and gonorrhea must be performed in a central lab, requiring patients to return to their health care provider for treatment should the results be positive.

    By providing diagnostic tests that can be performed at the point of care, delivering test results within minutes, could help ensure more patients with chlamydia and gonorrhea are tested and receive treatment, potentially interrupting the transmission cycle.

    Bridging the Technology Gap

    At Talis, we are pioneering science and technology to diagnose infectious disease rapidly, accurately, and directly at the point of care. Fueled by excellence and clinical rigor, we’re developing a robust menu of tests to advance health equity and outcomes.

    One System, Multiple Applications

    With access to lab-quality molecular diagnostics at the point of need, clinicians get timely results for actionable decision making. In the future, our portfolio of point-of-care diagnostic tests will include solutions for multiple infectious disease states in a variety of settings.

    Learn more about our Talis One COVID-19 Instrument

    Meet the Talis One

    References

    1. Institute of Medicine Committee on Prevention and Control of Sexually Transmitted Diseases. The Hidden Epidemic: Confronting Sexually Transmitted Diseases, Summary. National Academies Press; 1997. eds. Washington, DC:   https://www.ncbi.nlm.nih.gov/books/NBK232935/. Eng. TR, Butler WT.
    2. National Academy of Public Administration; The STD Epidemic in America: The Frontline Struggle. November 19, 2019. http://www.ncsddc.org/wp-content/uploads/2019/11/NCSD-Phase-II-Final-Report.pdf
    3. Sexually Transmitted Diseases. https://www.healthypeople.gov/2020/topics-objectives/topic/sexually-transmitted-diseases
    4. Division of Epidemiology and Disease Prevention- Sexually Transmitted Diseases (STDs). https://www.ihs.gov/Epi/std/overview/.
    5. Sexually Transmitted Infections Among US Women and Men: Prevalence and Incidence Estimates, 2018. Sexually Transmitted Diseases: April 2021 – Volume 48 – Issue 4 – p 208-214. https://pubmed.ncbi.nlm.nih.gov/33492089/. Kreisel KM, Spicknall IH, Gargano JW, Lewis FMT, Lewis RM, Markowitz LE, Roberts H, Johnson AS, Song R, St Cyr SB, Weston EJ, Torrone EA, Weinstock HS.
    6. Centers for Disease Control and Prevention (CDC) – Sexually Transmitted Diseases (STDs) – STI Treatment Guidelines, 2021. https://www.cdc.gov/std/treatment-guidelines/intro.htm.
    7. World Health Organization (WHO) – Sexually transmitted infections (STIs). https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis).
    8. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Disease Surveillance 2019. https://www.cdc.gov/std/statistics/2019/infographic-html.htm.
    9. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Disease Surveillance 2020. https://www.cdc.gov/std/statistics/2020/overview.htm#Disparities. https://www.cdc.gov/std/statistics/2020/overview.htm
    10. Centers for Disease Control and Prevention (CDC). NCHHSTP Social Determinants of Health. https://www.cdc.gov/nchhstp/socialdeterminants/faq.html#what-is-health-equity.
    11. Centers for Disease Control and Prevention (CDC). Health Equity. https://www.cdc.gov/healthequity/index.html.
    12. Sexually Transmitted Disease Surveillance, 2019. https://www.cdc.gov/std/statistics/2019/foreword.htm.
    13. U.S. Department of Health and Human Services. The Secretary’s Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2020. Phase I report: Recommendations for the framework and format of Healthy People 2020 [Internet]. Section IV: Advisory Committee findings and recommendations [cited 2010 January 6]HealthyPeople.Gov. Foundation Health Measures – Foundation Health Measures Archive – Disparities. https://www.healthypeople.gov/2020/about/foundation-health-measures/Disparities.
    14. “Point of care diagnostics for sexually transmitted infections: perspectives and advances.” Expert review of anti-infective therapy vol. 12,6 (2014): 657-72. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065592/. Gaydos, Charlotte, and Justin Hardick.
    15. “What’s the Point? How Point-of-Care STI Tests Can Impact Infected Patients.” Point of care vol. 9,1 (2010): 36-46. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853950/. Huppert, Jill et al.
    16. United States Preventative Task Force (USPSTF) Chlamydia and Gonorrhea: Screening. September 14, 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydia-and-gonorrhea-screening.
    17. Centers for Disease Control and Prevention (CDC). CDC. Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae — 2014. MMWR 2014;63(No. RR-2). Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae — 2014. https://www.cdc.gov/std/laboratory/2014labrec/default.htm.
         

    Related Articles

    Article
    July 18, 2022

    Summer Travel 2022 – We’re Still in a Pandemic

    In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
    Article
    June 15, 2022

    Sexually Transmitted Infections and Disease: the Silent Pandemic

    Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
    Article
    May 13, 2022

    COVID-19: It’s Not Over Yet

    It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
    Article
    March 16, 2022

    COVID-19 Testing for Travel—What Your Patients Need to Know

    Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

    Join Our Newsletter

    Subscribe to our newsletter for information about our products and company updates.


      TALIS BIOMEDICAL

      The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

      © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

      *Additional testing solutions are currently in development and not available for sale.

      COVID-19: It’s Not Over Yet

           

      It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the scientific world and public health communities all came together to identify the cause of this outbreak, to understand the type of “virus” infecting people and identify the infectious “disease” causing so many deaths around the world.

      Fast forward to the first five months of 2022, where we now find ourselves removing COVID-19 restrictions at the same time cases are rising in the U.S. due to the “newest” Omicron subvariant BA.2.12 and BA2.12.11 wave.

      How many SARs-CoV-2 variants of concern (VOC) are there?

      What We Know about Omicron

      It’s amazing how much we have learned about COVID-19 during these past two years of the pandemic. SARS-CoV-2, like other RNA viruses2, is prone to genetic evolution while adapting to their new human hosts with the development of mutations over time, resulting in the emergence of multiple variants that may have different characteristics compared to its ancestral strains. Viruses mutate all the time, but only some mutations affect their ability to spread or evade prior immunity from vaccination or infection, or the severity of disease they cause.

      The evolution of the SARS-CoV-2 virus over the course of the COVID-19 pandemic has resulted in the emergence of five variants of concern (VOC)3—Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) Delta (B.1.617.2) and Omicron (B.1.1.529): —to date. In late December 2021, Omicron overtook Delta as the dominant variant in the U.S, and by the end of April 2022, surpassed the original Omicron strain to become the predominant COVID-19 variant in the U.S.

      The Omicron variant, officially known as B.1.1.529, of SARS-CoV-2 has three main subvariants in its lineage4: BA.1, BA.2 and BA.3. Omicron has also undergone 50 mutations when compared to its previous variants of SARS-CoV-2: Alpha, Beta, Gamma, and Delta, and it is found to be the most prominent and distinct VOC as the spike protein of Omicron has 26 amino acid mutations from the millions of SARS-CoV-2 genomes.5

      The BA.1 subvariant has over 30 mutations6 in the spike protein that helps it enter cells. Spike protein mutations7 are of high concern to scientists and public health officials because they affect how infectious a particular variant is and whether it is able to escape the protective antibodies that the body produces after vaccination or a prior COVID-19 infection.

      BA.2 or the “stealth variant” has eight unique mutations that make it more transmissible than the original Omicron variant, but lacks the 13 mutations that BA.1 has. BA.2 does, however, share around 30 mutations with BA.1.8

      XE: A hybrid variant of Omicron

      The XE sub-variant is a recombinant hybrid strain of Omicron BA.1 and BA.2 that contains mutations found in both variants. A recombinant occurs when two or more variants of the virus infects the same cell, in the same person, at the same time, and combines their genetic material.9 Omicron XE appears to be more transmissible than Omicron BA.2, which appears to be more transmissible than Omicron BA.1.

      Is Omicron more transmissible than previous variants?

      According to the CDC, the Omicron variant spreads more easily than the original SARS-CoV-2 virus and the Delta variant. BA.2 shares many genetic similarities with its BA.1 subvariant, but BA.2 is between 30 percent and 50 percent more contagious than BA.1, appears to spread even faster that BA.1, but it does not appear to cause more severe disease than BA.1.10

      A continued need for POC COVID-19 molecular testing

      While the COVID-19 virus is still with us and continues to evolve, we should expect to see new variants emerge and disappear as they compete against each other and other circulating viruses. We should continue to protect ourselves and use the tools that we have at our disposal to respond to this ongoing pandemic.

      COVID-19 testing is critical and remains important to help keep life moving forward, as new variants may continue to emerge.13 While there are many different types of tests that have emergency use authorization (EUA) in the United States, including molecular diagnostics/nucleic acid amplification tests (NAAT), antigen tests, and serological tests, molecular testing remains the gold standard for identifying SARS-CoV-2 infection.11

      “Current diagnostic tests for the SARS-CoV-2 pandemic use nucleic acid, antibody and protein-based detections, but viral nucleic acid detection by RT–PCR remains the gold standard.”

      –Kevadiya, et al.12

      Talis One™: The next big thing in COVID-19 molecular testing

      At Talis, we believe that accurate POC molecular tests that can provide results in minutes instead of hours are needed to meet the need for fast, accurate testing. But not all POC NAATs deliver the same accuracy and sensitivity that central lab NAATs deliver12, which is why we developed the Talis One COVID-19 Test System.

      Designed to deliver central lab quality NAAT results quickly and in a variety of care environments, the Talis One COVID-19 Test System is the answer for rapid, POC COVID-19 molecular testing needs. Unlike other POC COVID-19 tests that may not be as sensitive, the Talis One COVID-19 Test System achieves lab-quality detection thanks to our proprietary on-cartridge sample extraction step and other patented technologies that give our assay a limit of detection (LOD) of 500 copies/mL.

      Learn more about our Talis One COVID-19 Test System

      Meet the Talis One

      References

      1. CDC Tracker Interpretive Summary for April 22, 2022. Unpacking Variants. J Phys Chem Lett Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant 2022 May 5;13(17):3840-3849. Epub 2022 Apr 25.
      2. National Library of Medicine – Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19) 2022 Feb 6. Aleem A, Akbar Samad AB, Slenker AK.
      3. National Library of Medicine – Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19) 2022 Feb 6. Aleem A, Akbar Samad AB, Slenker AK.
      4. CDC-COVID-19 SARS-CoV-2 Variant Classifications and Definitions
      5. Eur Phys J Plus. 2022; 137(1): 100. – Published online 2022 Jan 10 doi: 10.1140/epjp/s13360-021-02321-y.
      6. Acta Pharmacologica Sinica- Review Article. Published: 03 August 2020. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Huang, Y., Yang, C., Xu, Xf. et al.
      7. Acta Pharmacologica Sinica volume 41, pages 1141–1149 (2020). Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Huang, Y., Yang, C., Xu, Xf. et al.
      8. N Engl J Med 2022; 386:1579-1580. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.
      9. UK SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 40Security. What is Omicron XE Variant and is there cause for concern?
      10. MedRxiv and BioRxiv. Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection. Posted February 22, 2022.
      11. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Published. 2021 Jan 22. doi:10.1093/cid/ciab048. Hanson KE, Caliendo AM, Arias CA, et al.
      12. Diagnostics for SARS-CoV-2 infections. Nat Mater. Published 2021;20(5):593-605. doi:10.1038/s41563-020-00906-z. Kevadiya BD, Machhi J, Herskovitz J, et al.
      13. COVID-19 Testing: What You Need to Know – Updated May 3, 2022.
           

      Related Articles

      Article
      July 18, 2022

      Summer Travel 2022 – We’re Still in a Pandemic

      In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
      Article
      June 15, 2022

      Sexually Transmitted Infections and Disease: the Silent Pandemic

      Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
      Article
      May 13, 2022

      COVID-19: It’s Not Over Yet

      It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
      Article
      March 16, 2022

      COVID-19 Testing for Travel—What Your Patients Need to Know

      Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

      Join Our Newsletter

      Subscribe to our newsletter for information about our products and company updates.


        TALIS BIOMEDICAL

        The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

        © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

        *Additional testing solutions are currently in development and not available for sale.

        COVID-19 Testing for Travel—What Your Patients Need to Know

             

        Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are often very specific requirements on the type of test that will be accepted, and patients may be turning to their healthcare providers for advice. In this article, we provide links to relevant resources and a quick explanation of what qualifies as a nucleic acid amplification test (NAAT) COVID-19 test for travel purposes to help you provide your patients with effective advice.

        A PCR test vs a NAAT COVID-19 test for travel—what’s the difference?

        One question the Talis team frequently hears is if the Talis One™ COVID-19 Test System, which has been granted Emergency Use Authorization (EUA),can be used for travel testing. Patients have often heard the term “PCR” test when most of the time any NAAT will work. Consequently, many worry that if they don’t get a PCR test, the test won’t be valid as they are trying to board a domestic or an international flight.

        The technology in the Talis One COVID-19 Test System is a specific NAAT that falls under the category of isothermal amplification techniques. You can learn more about our technology here, but briefly, our tests use real-time loop-mediated isothermal amplification (rtLAMP) for DNA targets and real-time reverse transcription loop-mediated isothermal amplification (rtRT-LAMP) for RNA targets. This approach is recognized as a NAAT technology that is used for SARS-CoV-2 testing by the CDC.1

        Additional resources on COVID-19 testing for travel that your patients may want

        One of the biggest challenges with knowing which tests are valid is understanding the different jurisdictions and where to look for more information. Here are a few tips that your patients may find useful:

        For international travel, look for information based on your destination.

        Each country has their own rules about what is required for travel into the country, with a variety of mask mandates and acceptable tests which may vary based on vaccine status. For travel from the United States to other countries, the State Department has a page on their website where you can look up country-specific COVID-19 information.

        For Air Travelers to the U.S.A.

        For travel into the United States from a foreign country, all air passengers regardless of nationality or vaccination status, are required to show documentation of a negative COVID-19 viral test result taken within one day before travel, or documentation of having recovered from COVID-19 in the past 90 days, before they board their flight.

        For Land Travel to the U.S.A.

        Effective January 22, 2022, the Department of Homeland Security (DHC) requires non-U.S. individuals who are traveling for both essential and non-essential reasons and are seeking to enter the United States via land ports of entry (POE) and ferry terminals at the U.S-Mexico and U.S-Canada borders, to be fully vaccinated for COVID-19 and provide related proof of vaccination, as COVID-19 cases continue to rise nationwide. This restriction does not apply to U.S. citizens, Lawful Permanent Residents, or U.S. nationals. Learn more about land travel requirements from DHS.

        For travel within the United States, also look for information based on your destination.

        While at the time of writing this article, most states are fully open and do not require COVID-19 testing for the fully vaccinated, the emergence of variants and local surges can alter conditions rapidly. One place to look for information at the state level is at each state’s health department. You can find links to each states, cities, and county health departments on the CDC’s website.

        Note that some counties and cities may have more stringent requirements than the state they are in, so be sure to check those public health departments as well.

        The emergence of viral variants and local COVID-19 surges can alter conditions quickly, so we recommend regular review of the relevant websites before and during travel.

        New developments at Talis: Adding to our COVID-19 testing options, we now distribute the GenBody COVID-19 Antigen Test, a lateral flow test that delivers results in 15 minutes and can meet requirements for COVID-19 testing for travel if a lateral flow antigen test is accepted.

             

        Related Articles

        Article
        July 18, 2022

        Summer Travel 2022 – We’re Still in a Pandemic

        In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
        Article
        June 15, 2022

        Sexually Transmitted Infections and Disease: the Silent Pandemic

        Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
        Article
        May 13, 2022

        COVID-19: It’s Not Over Yet

        It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
        Article
        March 16, 2022

        COVID-19 Testing for Travel—What Your Patients Need to Know

        Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

        Join Our Newsletter

        Subscribe to our newsletter for information about our products and company updates.


          TALIS BIOMEDICAL

          The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

          © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

          *Additional testing solutions are currently in development and not available for sale.

          References

          1. CDC. CDC – Nucleic acid amplification tests (NAATs). Centers for Disease Control and Prevention. Published February 11, 2020. Accessed November 6, 2021.

          Omicron and COVID-19 testing: What healthcare providers need to know

               

          As the SARS-CoV-2 omicron variant (B.1.1.529) rapidly became the dominant strain in South Africa in late 2021, public health officials around the globe recognized that a new, highly transmissible form of the virus was likely emerging.1,2 However, understanding the specifics of what was different about omicron remained to be seen. Beyond higher transmissibility, questions around disease severity, vaccine effectiveness, and the time course of the disease were yet to be uncovered.

          Now, in just a few short months since omicron was initially identified, a clearer picture of the variant is coming into focus. And with that clearer picture of omicron’s complex biology, we have a better understanding of how our testing practices need to adjust. In this article, we’ll provide a quick summary of what we now know about omicron, how that affects testing strategies, and what we can learn to be prepared for future variants.

          What we know about omicron so far

          Omicron carries many mutations1

          Compared to the original SARS-CoV-2 alpha strain (B.1.1.7), the genome of the omicron variant carries over 60 different mutations.1 More than half of omicron’s mutations are in the spike protein,1 which mediates cell attachment and entry.3 Interestingly, as with all of the SARS-CoV-2 variants of concern, the omicron spike protein carries the D614G mutation that is associated with higher viral loads in the upper respiratory tract and a younger patient age range.1 Other mutations in the spike protein are associated with functionality that is expected to enhance infectivity.1

          Omicron is likely capable of at least partial immune evasion4–6

          Evidence reported in preprints suggests that omicron can evade immunity from previous infections4–6 and vaccinations,5 leading to reinfection, as well as infection of vaccinated individuals. However, one of the studies is reporting that prior infection and vaccination do protect against hospitalization and death.6

          Omicron is likely to cause less severe disease7

          An analysis of COVID-19 patients in Southern California, including 52,297 cases infected with the omicron variant and 16,982 cases with the delta variant, suggests that omicron causes less severe disease than delta, even when you take into account vaccination status or previous SARS-CoV-2 infection.7 The caveat to this study is that it is still in the preprint stage and has yet to be peer-reviewed.

          Omicron likely reproduces faster8,9 and may have a shorter incubation period10,11

          Faster reproducibility is one of the critical features of omicron that may help explain its ability to out-compete other variants, such as delta, to become the dominant strain in a region.8,9 Two studies still in the preprint stage report that the mean serial interval for omicron is 2.2 days8 and between 1.5 and 3.2 days.9 In contrast, reports of the mean generation time for delta spans a range of 3.3 – 4.24.8,12,13

          Early indications suggest that omicron also has a shorter incubation period than other variants. One early study in Denmark found a median incubation period of 3 days for omicron10, compared with 4.3 and 5.0 days for delta and other variants11, respectively.

          What this means for testing

          Given omicron’s large mutational burden1 and the early indications that it can evade prior immunity,4–6 likely reproduces faster,8,9 and may have shorter incubation times,10,11 some public health agencies and healthcare systems are already rethinking their testing strategies.14,15

          Can PCR and antigen tests sensitively and accurately detect omicron?

          The first thing to consider about testing is whether the large mutational burden carried by omicron affects the sensitivity and accuracy of either nucleic acid amplification tests (NAATs) like PCR or rapid antigen tests that rely on lateral flow technology.

          A January 22, 2022, technical brief from the World Health Organization (WHO) observes that the diagnostic accuracy of the PCR and rapid antigen tests listed in their emergency use list (EUL) is not significantly affected by the omicron variant,15 although one of the deletions in the gene encoding the spike protein, the S gene ?69-70, can cause S gene target failure (SGTF) in some NAATs.

          In addition, the Infectious Diseases Society of America (IDSA) is reporting that preliminary evidence suggests no loss in accuracy of currently available NAATs16 and that antigen tests are mostly based on detecting the nucleocapsid protein and should therefore be unaffected by the mutations in omicron.16

          Both the GenBody COVID-19 Ag Test and the Talis One™? COVID-19 Test System are expected to accurately detect the new coronavirus variant omicron based on initial in silico studies.*

          Does omicron affect testing frequency?

          While the CDC has not made any updates to their testing recommendations in response to omicron,17,18 the shorter generation and incubation times are leading some physicians to recommend frequent serial testing with rapid tests.19

          What can we learn from omicron?

          Emerging just as much of the world was beginning to relax COVID-19 protection measures, the omicron variant drove huge surges in infection rates, especially in the United States.20 The good news is that, as the CDC notes, “we have the tools to fight omicron”.18 Vaccines, masks, and testing are all effective tools that remain highly effective against omicron.18 What’s critical is that we keep on the lookout for the emergence of new variants and adjust our practices as quickly as we can based on initial and evolving evidence.

          Talis is proud of our part in delivering pandemic-mitigating solutions, with the GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System.

               

          Related Articles

          Article
          July 18, 2022

          Summer Travel 2022 – We’re Still in a Pandemic

          In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
          Article
          June 15, 2022

          Sexually Transmitted Infections and Disease: the Silent Pandemic

          Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
          Article
          May 13, 2022

          COVID-19: It’s Not Over Yet

          It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
          Article
          March 16, 2022

          COVID-19 Testing for Travel—What Your Patients Need to Know

          Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

          Join Our Newsletter

          Subscribe to our newsletter for information about our products and company updates.


            TALIS BIOMEDICAL

            The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

            © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

            *Additional testing solutions are currently in development and not available for sale.

            References

            1. He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant: Characteristics and prevention. MedComm. 2021;2(4):838-845. doi:10.1002/mco2.110
            2. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. Published online January 7, 2022:1-10. doi:10.1038/s41586-022-04411-y
            3. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117(21):11727-11734. doi:10.1073/pnas.2003138117
            4. Altarawneh H, Chemaitelly H, Tang P, et al. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. medRxiv. Published online January 1, 2022:2022.01.05.22268782. doi:10.1101/2022.01.05.22268782
            5. Yang W, Shaman J. SARS-CoV-2 transmission dynamics in South Africa and epidemiological characteristics of the Omicron variant. medRxiv. Published online January 1, 2021:2021.12.19.21268073. doi:10.1101/2021.12.19.21268073
            6. Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv. Published online January 1, 2021:2021.11.11.21266068. doi:10.1101/2021.11.11.21266068
            7. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. medRxiv. Published online January 1, 2022:2022.01.11.22269045. doi:10.1101/2022.01.11.22269045
            8. Kim D, Jo J, Lim JS, Ryu S. Serial interval and basic reproduction number of SARS-CoV-2 Omicron variant in South Korea. medRxiv. Published online January 1, 2021:2021.12.25.21268301. doi:10.1101/2021.12.25.21268301
            9. Abbott S, Sherratt K, Gerstung M, Funk S. Estimation of the test to test distribution as a proxy for generation interval distribution for the Omicron variant in England. medRxiv. Published online January 1, 2022:2022.01.08.22268920. doi:10.1101/2022.01.08.22268920
            10. Brandal LT, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Eurosurveillance. 2021;26(50):2101147. doi:10.2807/1560-7917.ES.2021.26.50.2101147
            11. Grant R, Charmet T, Schaeffer L, et al. Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. Lancet Reg Health – Eur. 2021;0(0). doi:10.1016/j.lanepe.2021.100278
            12. Hwang H, Lim JS, Song SA, et al. Transmission Dynamics of the Delta Variant of SARS-CoV-2 Infections in South Korea. J Infect Dis. Published online December 2, 2021:jiab586. doi:10.1093/infdis/jiab586
            13. Li L, Han ZG, Qin PZ, et al. Transmission and containment of the SARS-CoV-2 Delta variant of concern in Guangzhou, China: A population-based study. PLoS Negl Trop Dis. 2022;16(1):e0010048. doi:10.1371/journal.pntd.0010048
            14. Omicron Guidance Updates | Nebraska Medicine Omaha, NE. Accessed January 26, 2022.
            15. Enhancing response to Omicron SARS-CoV-2 variant. Accessed January 26, 2022.
            16. Vaccines FAQ. Accessed January 26, 2022.
            17. CDC. Healthcare Workers. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed January 26, 2022.
            18. CDC. Omicron Variant: What You Need to Know. Centers for Disease Control and Prevention. Published December 20, 2021. Accessed January 27, 2022.
            19. Godoy M. Why rapid COVID tests aren’t more accurate and how scientists hope to improve them. NPR. Published January 23, 2022. Accessed January 26, 2022.
            20. CDC. COVID Data Tracker. Centers for Disease Control and Prevention. Published March 28, 2020. Accessed September 24, 2021.

            *Internal test data on file and available upon request.

            What is the difference between NAAT and PCR?

                 

            While the COVID-19 pandemic has brought phrases like “PCR test” and “antigen test” into wider use, one term that hasn’t been talked about as much is “NAAT,” which is short for nucleic acid amplification test (Figure 1).1 As the media has widely reported,2–7 most rapid COVID tests are antigen-based. Antigen tests are better at assessing if a person is infectious at the time of the testing rather than if they are carrying the SARS-CoV-2 virus, while lab-based PCR tests are better able to detect if a person has the virus.2,3,5–7

            If you’re a healthcare professional or facility manager looking for a point-of-care testing system that can help support a COVID-free environment, you may be wondering where NAATs fit into all of this. There are some rapid tests that are not antigen tests and not PCR tests, but rather are described as NAATs. We’ve already covered the difference between antigen and molecular tests in another blog post . In this article, we’ll discuss the differences between NAAT and PCR, focusing on point-of-care testing for COVID-19 and other infectious diseases.

            Figure 1. Google Trends shows the increased search volume for “antigen test” and “PCR test” in the months after the start of the COVID-19 pandemic.1

            PCR is a type of NAAT8

            The quick answer to “what is the difference between NAAT and PCR” is that PCR is a type of NAAT. Not every NAAT uses PCR methodology, but all PCR tests are a type of NAAT.8

            The term “NAAT” applies to a range of different technologies where nucleic acid, i.e., RNA or DNA, from a pathogen is amplified and detected to determine if a pathogen is present.8 Typically, if the pathogen is a virus with an RNA genome like SARS-CoV-2 and influenza, the first step in the NAAT method will be to convert the RNA into DNA using a reverse transcriptase and then amplify the DNA.

            Different NAATs approach nucleic acid amplification in different ways.8

            PCR

            The lab-based COVID-19 test that is considered the gold-standard uses real-time reverse transcriptase PCR (RT-PCR), which converts SARS-CoV-2 RNA into DNA and then amplifies the DNA by cycling it through different temperatures.9 By including a high temperature step in each cycle, the two DNA strands are separated, and each strand replicated, enabling the generation of many copies of the same DNA sequence from a single molecule.10

            When PCR is used in lab tests, the process can take hours because of the need to extract the nucleic acid from the specimen11 and because the sample is typically run through thirty or more cycles of several minutes each (for a description of the COVID-19 testing process that is accessible to a general reader, see this article from NPR12).

            Isothermal methods

            Because PCR is a complex process that can take hours to perform,11 it is less suitable for a point-of-care test where results are needed in thirty minutes or less. To address this challenge, several diagnostics developers have focused on nucleic acid amplification methods that do not require multi-temperature cycles, such as RT-LAMP technology. This collection of techniques is referred to as “isothermal” because amplification is conducted at a single temperature.13, 14 Amplification can be achieved in minutes, instead of hours, using different enzymatic techniques to separate the two DNA strands prior to replication.13, 14

            To learn more about the RT-LAMP technology used in Talis One, read the article “The Technology Behind the Talis One Molecular Point of Care Test”

            View article

            Not every NAAT delivers the same performance, especially point-of-care NAATs

            From a practical point-of-view, you may be wondering if NAATs, especially point-of-care NAATs, can deliver the same quality results as lab-based PCR tests? When it comes to COVID-19, not every NAAT does,15 although more studies in real-world conditions are needed to confidently address this question.15

            The Talis One COVID-19 Test System includes a nucleic acid extraction step to achieve central lab-level performance

            One possible reason that some point-of-care NAATs don’t perform as well as lab-based PCR tests is that they don’t include a nucleic acid extraction step.11 While this saves time, compounds in the sample can potentially inhibit the amplification step.11 This is why the Talis team developed an instrument, the Talis One, that performs a solid-phase sample extraction step within the Talis One test cartridge; this enables the test system to achieve central lab-level performance.16

            Learn more about our Talis One COVID-19 Test System

            Meet the Talis One

            The difference between NAAT and PCR: non-PCR NAAT’s hold great promise for fast and accurate testing at the point of care

            Bringing the sensitivity and specificity of PCR to the point of care requires looking beyond PCR to isothermal NAAT methods.13, 14 Whether these tests are used for the ongoing COVID-19 pandemic or for other infectious diseases, non-PCR NAAT’s hold great promise for ensuring fast and accurate test results in a variety of care settings.13, 14

                 

            Related Articles

            Article
            July 18, 2022

            Summer Travel 2022 – We’re Still in a Pandemic

            In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
            Article
            June 15, 2022

            Sexually Transmitted Infections and Disease: the Silent Pandemic

            Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
            Article
            May 13, 2022

            COVID-19: It’s Not Over Yet

            It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
            Article
            March 16, 2022

            COVID-19 Testing for Travel—What Your Patients Need to Know

            Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

            Join Our Newsletter

            Subscribe to our newsletter for information about our products and company updates.


              TALIS BIOMEDICAL

              The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

              © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

              *Additional testing solutions are currently in development and not available for sale.

              References

              1. Google Trends. Google Trends. Accessed November 6, 2021.
              2. How Accurate Are At-Home COVID Tests? Here’s What Experts Say. NBC Chicago. Accessed November 6, 2021.
              3. Rapid COVID-19 Tests: When to Use Them and How They Work. Healthline. Published October 13, 2021. Accessed November 6, 2021.
              4. Parker-Pope T. How to Use Rapid Home Tests (Once You Find Them). The New York Times. Published October 8, 2021. Accessed November 6, 2021.
              5. The differences to know between COVID tests as gatherings begin for the holidays. Masslive. Published November 5, 2021. Accessed November 6, 2021.
              6. Santora T. The Smartest Way to Use Rapid At-Home COVID Tests. Scientific American. Accessed November 6, 2021.
              7. Hartmann M. Where Are All the At-Home COVID Tests? Intelligencer. Published October 27, 2021. Accessed November 6, 2021.
              8. CDC – Nucleic acid amplification tests (NAATs). Centers for Disease Control and Prevention. Published February 11, 2020. Accessed November 6, 2021.
              9. How is the COVID-19 Virus Detected using Real Time RT-PCR? Published March 27, 2020. Accessed November 18, 2021.
              10. Polymerase Chain Reaction (PCR) Fact Sheet. Genome.gov. Accessed November 6, 2021.
              11. Walker FM, Hsieh K. Advances in Directly Amplifying Nucleic Acids from Complex Samples. Biosensors. 2019;9(4):117. doi:10.3390/bios9040117
              12. Appleby J. Why It Takes So Long To Get Most COVID-19 Test Results. NPR.  Published March 28, 2020. Accessed November 6, 2021.
              13. Pumford EA, Lu J, Spaczai I, et al. Developments in integrating nucleic acid isothermal amplification and detection systems for point-of-care diagnostics. Biosens Bioelectron. 2020;170:112674. doi:10.1016/j.bios.2020.112674
              14. James AS, Alwneh JI. COVID-19 Infection Diagnosis: Potential Impact of Isothermal Amplification Technology to Reduce Community Transmission of SARS-CoV-2. Diagnostics. 2020;10(6):399. doi:10.3390/diagnostics10060399
              15. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point?of?care antigen and molecular-based tests for diagnosis of SARS?CoV?2 infection. Cochrane Database Syst Rev. 2021;2021(3):CD013705. doi:10.1002/14651858.CD013705.pub2
              16. Talis Bio. Evaluation of the Talis OneTM Covid-19 Test System for the Rapid Detection of Sars-Cov-2 and Emerging Variants. Published online 2021. Accessed October 29, 2021.

              3 Lessons from the emergence of the SARS-CoV-2 Delta variant

                   

              The emergence of the SARS-CoV-2 Delta variant highlights the importance of widespread vaccination and the ongoing need for accurate testing.

              New variants can quickly change the public health situation

              Positive developments related to the pandemic situation between the end of 2020 and early 2021 generated a great deal of hope. Multiple vaccines were starting to become available and by March 8, 2021, the CDC declared that fully vaccinated people could gather indoors without wearing masks.1 At that time, many believed that the worst of the pandemic was in the past. However, the emergence of the SARS-CoV-2 Delta variant significantly impacted the public health situation across much of the United States, with the CDC issuing new masking guidance and urging more people to become vaccinated in a July 27, 2021, announcement.2

              As we now know, the Delta variant is ~2x more contagious than previous variants,2-5 which has led to very rapid spread in areas with low vaccination rates.5 In the United States, the 7-day moving average of reported cases increased from ~12,000 in late June to ~60,000 by July 27.2 One of the main lessons the medical community can learn from the rapid spread of the Delta variant is how quickly a new variant can change the local public health situation from in to out of control. So how can we stop the emergence of new variants, one or more of which may be worse than Delta?

              Stopping the emergence of new variants requires controlling disease spread

              As with many viruses, the emergence of SARS-CoV-2 variants is the result of random errors introduced into the viral genome during replication.6 The best way to reduce the emergence of new variants is to limit virus replication by limiting transmission.7

              Variants are expected. The best way to slow the emergence of new variants is to reduce the spread of infection by taking measures to protect yourself, including getting a COVID-19 vaccine when available.7

              Until vaccination rates increase sufficiently to limit transmission, SARS-CoV-2 testing will continue to be needed

              Despite the effectiveness of vaccines in reducing the risk of death from SARS-CoV-2 and limiting disease spread, vaccine hesitancy remains a challenge.8,9 Given a vaccination level of ~55% of the total population in the United States,10 it seems plausible that we may see additional outbreaks from new variants, although Delta is the only variant of concern currently in the United States.11

              In addition, many scientists believe that COVID-19 is here to stay, becoming an endemic disease.12,13 Whether COVID-19, during its transition to endemicity, becomes a milder disease and/or a disease of the young,12,13 diagnostic testing will most likely continue to be an important tool for ensuring public health.

              The Talis One™ Instrument Delivers Accurate Molecular Testing at the Point of Care

              The Talis One COVID-19 Test System is conducted on the Talis One instrument which is designed to easily fit into a variety of care settings. The instrument is built to maximize health outcomes in the face of infectious disease threats, with an assay menu that will expand to include sexual and women’s health tests in the near future.

              Learn more about the Talis One COVID-19 Test System
                   

              Related Articles

              Article
              July 18, 2022

              Summer Travel 2022 – We’re Still in a Pandemic

              In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
              Article
              June 15, 2022

              Sexually Transmitted Infections and Disease: the Silent Pandemic

              Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
              Article
              May 13, 2022

              COVID-19: It’s Not Over Yet

              It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
              Article
              March 16, 2022

              COVID-19 Testing for Travel—What Your Patients Need to Know

              Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

              Join Our Newsletter

              Subscribe to our newsletter for information about our products and company updates.


                TALIS BIOMEDICAL

                The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

                © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

                *Additional testing solutions are currently in development and not available for sale.

                References

                1. CDC. CDC Museum COVID-19 Timeline. Centers for Disease Control and Prevention. Published August 4, 2021. Accessed August 23, 2021. https://www.cdc.gov/museum/timeline/covid19.html
                2. CDC. Coronavirus Disease 2019 (COVID-19). Delta Variant: What We Know About the Science. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed September 24, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html
                3. Li B, Deng A, Li K, et al. Viral Infection and Transmission in a Large, Well-Traced Outbreak Caused by the SARS-CoV-2 Delta Variant.; 2021:2021.07.07.21260122. doi:10.1101/2021.07.07.21260122
                4. Wang Y, Chen R, Hu F, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine. 2021;40:101129. doi:10.1016/j.eclinm.2021.101129
                5. Bian L, Gao Q, Gao F, et al. Impact of the Delta variant on vaccine efficacy and response strategies. Expert Rev Vaccines.:1-9. doi:10.1080/14760584.2021.1976153
                6. Chen J, Wang R, Wei G-W. Review of the mechanisms of SARS-CoV-2 evolution and transmission. ArXiv. Published online September 15, 2021:arXiv:2109.08148v1.
                7. CDC. Coronavirus Disease 2019 (COVID-19). What you need to know about variants. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed September 24, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html
                8. Tram KH, Saeed S, Bradley C, et al. Deliberation, Dissent, and Distrust: Understanding Distinct Drivers of Coronavirus Disease 2019 Vaccine Hesitancy in the United States. Clin Infect Dis Off Publ Infect Dis Soc Am. Published online July 16, 2021:ciab633. doi:10.1093/cid/ciab633
                9. Siegler AJ, Luisi N, Hall EW, et al. Trajectory of COVID-19 Vaccine Hesitancy Over Time and Association of Initial Vaccine Hesitancy With Subsequent Vaccination. JAMA Netw Open. 2021;4(9):e2126882. doi:10.1001/jamanetworkopen.2021.26882
                10. CDC. COVID Data Tracker. Centers for Disease Control and Prevention. Published March 28, 2020. Accessed September 24, 2021. https://covid.cdc.gov/covid-data-tracker
                11. CDC. Coronavirus Disease 2019 (COVID-19). SARS-CoV-2 Variant Classifications and Definitions. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed September 24, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
                12. Torjesen I. Covid-19 will become endemic but with decreased potency over time, scientists believe. BMJ. 2021;372:n494. doi:10.1136/bmj.n494
                13. Phillips N. The coronavirus is here to stay — here’s what that means. Nature. 2021;590(7846):382-384. doi:10.1038/d41586-021-00396-2

                Addressing Healthcare disparities in the US with Point-of-Care Testing

                     

                Healthcare disparities in the US have become strikingly apparent throughout the COVID-19 pandemic, affecting historically underserved populations (e.g., lower-income households, Black and Minority Americans, immigrants, people with disabilities, rural populations, etc.). Point-of-care (POC) testing can help. To reduce the spread of infections and bring health equity forward, we need to take a closer look at POC testing and how to get it to communities that need it most.

                Healthcare disparities in the US at the point of care

                The rapidity of spread and mortality associated with the COVID-19 pandemic has shined a light on health disparities in the US. COVID-19 infection is higher among groups already affected by health disparities across age, race, ethnicity, language, income, and living conditions.1 Since the beginning of the pandemic, the top-third of vulnerable counties (defined by the COVID-19 vulnerability Index) have seen 21% more cases and 47% more deaths than the bottom-third of vulnerable counties, despite receiving 27% fewer tests.2 3

                One study found that transportation barriers are associated with significantly higher odds of a positive COVID-19 test, which suggests a greater risk of disease exposure associated with reliance on public transit and/or shared rides, or it may suggest inadequate access to health care, including timely COVID-19 testing.1 What’s more, COVID-19 has shifted the utilization of the American healthcare system where individuals are delaying or forgoing care—which can have serious and life-threatening health consequences. By June 2020, over 40% of U.S. adults reported that they delayed health care due to COVID-19 concerns.4

                Adding to these challenges is the threat of false negative COVID-19 test results, which could potentially lead to positive case clusters.5 6 When false negatives are suspected, individuals have to leave the facility and wait for their reflex testing results to become available. Ideally, individuals awaiting reflex testing results (as well as those who receive a positive COVID-19 test result) will quarantine, but this is not always possible, especially for those relying on public transportation and living in overcrowded housing facilities.

                Minimizing the time it takes to get accurate results and being able to communicate those results to patients quickly is paramount for minimizing community spread and delivering proper treatment. This supports the need for rapid and reliable testing, as well as in-visit test-to-answer POC workflows—especially for communities that have been shown to have less access to medical care and are less inclined to use telehealth service.

                What Point-of-Care Diagnostic Tests Should Look Like

                To drive health equity forward, we need diagnostic testing to be more accessible and reliable for underserved populations.

                Point-of-care diagnostics should enable rapid and effective test-to-treat workflows all in one visit

                Because underserved populations are more likely to miss appointments due to transportation and are more likely to have limited access to telehealth,7-10 it is imperative that these individuals get the information and treatment they need while they are in the testing facility. To confidently make treatment decisions during the same visit, point of care diagnostic tests should be sensitive without compromising speed and operational efficiency.

                Not only will test-to-treat workflows at the point of care help detect disease and deliver proper care earlier, but it can help minimize health care expenses due to missed appointments and hospitalization. This approach is stressed in the Sexually Transmitted Infections National Strategic Plan (2021-2025), where several objectives are discussed to ensure continuity of care. The plan touches on expanding personnel training to enhance screening, testing, and treatment capabilities within a single facility, specialized programs, and integrated and collaborative approaches in settings that serve communities disproportionately affected by STIs, HIV, and viral hepatitis.11

                The Talis Solution: A sample-to-answer test with central-lab quality sensitivity

                • The Talis One COVID-19 test enables quick and secure collection of samples for infectious disease testing
                • Talis One provides lab-quality molecular diagnostic results by utilizing innovative nucleic acid amplification technology integrated with solid-phase nucleic acid purification
                • Compared with up to several days of wait time for lab-run tests with similar accuracy, the Talis One solution delivers clear results in less than 30 mins

                Point-of-care diagnostics should be flexible enough to adapt to different environments and different communities

                Point-of-care locations can range from large pop-up centers in rural areas and places of work to metropolitan mobile clinics. Each community is unique, and POC tests need to be adaptable to the specific needs of the community. The instruments being used to detect SARS-CoV-2 should be space efficient for multiple types of facilities and, ideally, flexible enough to test for multiple infectious diseases and disease variants that are prevalent in the community being tested. This can save time for both the individual and the testing facility.

                As suggested by the Office of the Assistant Secretary of Health (OASH) and Office of Minority Health (OMH), to expand access to communities that are unable to access traditional testing sites, the federal government should partner with test kit manufacturers to develop SARS-CoV-2 test kits that are flexible enough to be used at the point of care or at-home and should establish and enforce policies that require public and private health insurance to cover SARS-CoV-2 testing to minimize financial barriers.12

                The Talis Solution:

                • Talis One is a complete, cost-effective solution that has potential for menu expansion to infectious diseases in respiratory and women’s health
                • With its small footprint and streamlined sample-to-answer workflow, Talis One can be used in a variety of point-of-care settings, enabling easy and broad access to testing for patients

                Point-of-care diagnostics should be easy-to-implement and easy-to-use

                Adopting new healthcare technologies is resource intensive—requiring a substantial amount of time for implementation and training. With healthcare personnel shortages increasing in underserved areas,13 it can be difficult to maintain an efficient operational workflow, or worse, patients cannot get the tests they need because there aren’t enough people to perform them. POC testing needs to be easy to implement and intuitive so that facilities can get up and running as quickly as possible and maintain efficiency through personnel changes.

                The Talis Solution:

                • Talis One’s user-centric workflow makes it easy to quickly begin testing in a variety of CLIA- waived healthcare settings
                • Talis provides on-demand support and training including access to educational resources and implementation guides

                Point-of-care diagnostics should have features that streamline reporting and communication to patients, labs and governing bodies

                Timely reporting is essential for sharing results, monitoring where outbreaks occur, tracking the incidence and prevalence of infection, and evaluating the impact of interventions. Not only can it help determine if a newly placed mobile clinic is effective and quickly get test results to patients, but it also enables proper allocation of critical resources to those in greatest need.

                The Talis Solution:

                • Talis One has cloud connectivity that easily integrates with LIS and EMR systems
                • Results from the Talis One molecular tests are delivered as easy-to-understand reports
                • With sample-to-answer workflow, Talis One enables caregivers to communicate results to patients within 30 minutes

                Moving Towards Health Equity with Point-of-Care Testing

                With the CDC planning to invest $2.25 Billion to address COVID-19-related health disparities and advance health equity among populations that are at high-risk and underserved,14 there is no better time than now to evaluate and adopt a new POC testing solution.

                To ensure there is timely and equitable access to testing with rapid return of results in communities disproportionately affected by COVID-19, we need to consider the recommendations outlined by the CDC:1 5

                • Use a social vulnerability index16 to help select testing sites
                • Review the groups to prioritize for screening testing
                • Carefully consider the different types of SARS-CoV-2 tests when planning for diagnostic or screening use

                By providing easy access to actionable results at the point-of-care in public health settings, the Talis One molecular testing solution empowers you to quickly and confidently diagnose infections, promote safety and peace of mind for your patients, and ultimately combat healthcare disparities in the US.

                Learn More
                     

                Related Articles

                Article
                July 18, 2022

                Summer Travel 2022 – We’re Still in a Pandemic

                In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
                Article
                June 15, 2022

                Sexually Transmitted Infections and Disease: the Silent Pandemic

                Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
                Article
                May 13, 2022

                COVID-19: It’s Not Over Yet

                It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
                Article
                March 16, 2022

                COVID-19 Testing for Travel—What Your Patients Need to Know

                Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

                Join Our Newsletter

                Subscribe to our newsletter for information about our products and company updates.


                  TALIS BIOMEDICAL

                  The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

                  © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

                  *Additional testing solutions are currently in development and not available for sale.

                  References

                  1. Rozenfeld, Yelena, et al. “A model of disparities: risk factors associated with COVID-19 infection.” International journal for equity in health 19.1 (2020): 1-10.
                  2. Bringing Greater Precision to the COVID-19 Response. (2020, December). Retrieved July 01, 2021, from https://precisionforcovid.org/ccvi
                  3. Smittenaar, P., Stewart, N., Sutermaster, S., Coome, L., Dibner-Dunlap, A., Jain, M., … & Sgaier, S. K. (2021). A COVID-19 Community Vulnerability Index to drive precision policy in the US. medRxiv.
                  4. Czeisler, Mark É., et al. “Delay or avoidance of medical care because of COVID-19–related concerns—United States, June 2020.” Morbidity and mortality weekly report 69.36 (2020): 1250.
                  5. False negative rate of COVID-19 PCR testing: A discordant testing analysis. (2021, January 9). Retrieved July 01, 2021, from https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01489-0
                  6. Cao G, Tang S, Yang D, Shi W, Wang X, Wang H, et al. The potential transmission of SARS-CoV-2 from patients with negative RT-PCR swab tests to others: two related clusters of COVID-19 outbreak. Jpn J Infect Dis. 2020. https://doi.org/10.7883/yoken.JJID.2020.165.
                  7. Samuels, R. C., Ward, V. L., Melvin, P., Macht-Greenberg, M., Wenren, L. M., Yi, J., … & Cox, J. E. (2015). Missed appointments: factors contributing to high no-show rates in an urban pediatrics primary care clinic. Clinical pediatrics, 54(10), 976-982.
                  8. Fischer, S. H., Ray, K. N., Mehrotra, A., Bloom, E. L., & Uscher-Pines, L. (2020). Prevalence and characteristics of Telehealth utilization in the United States. JAMA network open, 3(10), e2022302-e2022302.
                  9. Pierce, R. P., & Stevermer, J. J. (2020). Disparities in use of telehealth at the onset of the COVID-19 public health emergency. Journal of telemedicine and telecare, 1357633X20963893.
                  10. Vogels, E. (2021, June 22). Digital divide persists even as Americans with lower incomes make gains in tech adoption. Retrieved July 01, 2021, from https://www.pewresearch.org/fact-tank/2021/06/22/digital-divide-persists-even-as-americans-with-lower-incomes-make-gains-in-tech-adoption/
                  11. U.S. Department of Health and Human Services. 2020. Sexually Transmitted Infections National Strategic Plan for the United States: 2021–2025. Washington, DC.
                  12. COVID-19 Health Equity Task Force: Long COVID, PPE, Testing and Therapeutics Subcommittee Interim Recommendations. (2021, June 25). Retrieved July 01, 2021, from https://www.minorityhealth.hhs.gov/Assets/PDF/June-COVID19HETFSubcommitteesRecommendations-062521-508.pdf
                  13. Malayala, Srikrishna Varun, et al. “Primary care shortage in medically underserved and health provider shortage areas: Lessons from Delaware, USA.” Journal of Primary Care & Community Health 12 (2021): 2150132721994018.
                  14. CDC announces $2.25 billion to address Covid-19 health disparities in communities that are at high-risk and underserved. (2021, March 17). Retrieved July 01, 2021, from https://www.cdc.gov/media/releases/2021/p0317-COVID-19-Health-Disparities.html
                  15. Overview of Testing for SARS-CoV-2 (COVID-19). (2021, March 17). Retrieved July 01, 2021, from https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html
                  16. CDC/ATSDR Social Vulnerability Index. (2021, April 28). Retrieved July 01, 2021, from https://www.atsdr.cdc.gov/placeandhealth/svi/index.html

                  Antigen vs Molecular Test: Which type of COVID-19 test is more reliable?

                       

                  In the antigen vs molecular test debate, understanding which test is best is a matter of timing and application—the answer could change depending on how you’re using the test and how quickly you need the test results. In addition, the emergence of newer testing technologies may change the parameters of the debate, tipping the balance towards molecular testing for a number of situations.

                  To understand which test technology will work best for your application, let’s take a closer look at the pros and cons of each technology (note that for the sake of brevity, we are leaving the discussion of sample type for another article).

                  Molecular tests performed in a central lab are sensitive and specific, but take time to deliver results


                  What a molecular test detects

                  In general, molecular tests detect nucleic acid—either RNA or DNA.

                  Why this matters for diagnosing COVID-19

                  Molecular tests can detect the presence of SARS-CoV-2 even during the early stages of infection because they detect viral RNA, which can accumulate to high levels within a cell before virus particles are formed.

                  Benefits of molecular tests

                  Molecular tests are ideal for detecting emerging infectious diseases such as the SARS-CoV-2 virus because they are quick to develop and deploy.

                  Most molecular tests that are conducted in a central lab setting are very sensitive and specific, with commercially available SARS-CoV-2 molecular tests exhibiting >95% sensitivity and >99% specificity, with the potential to detect as little as a few dozen to a few hundred copies/mL of a nucleic acid sequence from the pathogen (i.e., they have low limits of detection (LOD)).1

                  Thus, molecular tests can detect disease in the very early stages of infection, when the viral load is fairly low.

                  Challenges of molecular tests

                  While the sensitivity and specificity of lab-conducted molecular tests is high and the LOD is low, the complexity of these tests typically restricts their use to the central lab setting. This adds time between when the sample is taken and when results are delivered. At best, the turnaround time can be as little as 24-48 hours, but at the height of the pandemic, some labs were experiencing turnaround times of as much as two weeks due to reagent shortages and insufficient testing throughput.

                  For highly infectious diseases like SARS-CoV-2, the delay in receiving test results can negatively impact both the patient—by potentially forcing them to quarantine while waiting for results—and public health, if an infectious patient does not quarantine while waiting for results.

                  Best applications for SARS-CoV-2 molecular tests

                  With their high sensitivity and specificity, SARS-CoV-2 molecular tests are often considered the gold standard for diagnosis. The Infectious Disease Society of America (ISDA) recommends molecular tests for symptomatic patients even if the suspicion of COVID-19 is low, and prefers that results be available within 48 hours.2

                  For asymptomatic patients, the ISDA recommends testing only in certain situations2, such as:

                  • Upon known or suspected exposure to COVID-19
                  • Upon admission to a hospital in an area with a high prevalence of COVID-19
                  • Before certain medical procedures

                  Antigen tests can be performed at the point-of-care, but are not as sensitive as molecular tests leading to higher false negative rates


                  What an antigen test detects

                  In general, an antigen test detects a protein that’s unique to the pathogen. For SARS-CoV-2 detection, the antigen tests detect a protein of the virus particle.

                  Why this matters for diagnosing COVID-19

                  Because antigen tests rely on production of virus particles, they can miss newly-infected patients that have virus replicating within their cells but have not yet produced measurable amounts of virus particles.

                  Benefits of antigen tests

                  Antigen tests are easy to conduct, inexpensive, and deliver results in minutes. They are also highly specific and can be done at the point-of-care.3

                  Challenges of antigen tests

                  The benefits of antigen testing are balanced by a lower sensitivity than molecular tests, with sensitivity dependent on whether or not symptoms are present and how long after symptom onset the test is given. For tests given within seven days of symptom onset, pooled antigen test sensitivity is 84%, dropping to 49% in asymptomatic individuals.3

                  The lower sensitivity can lead to a higher false negative rate, i.e., more missed infections, which restricts their usefulness to certain situations when molecular tests are widely available.

                  Best applications for SARS-CoV-2 antigen tests

                  While the ISDA recommends molecular tests over antigen tests for symptomatic individuals unless test results will not be delivered within three days, their recommendations for asymptomatic individuals are neither for nor against antigen testing due to a lack of sufficient evidence either way.3

                  That said, a more recent simulation study based on real-world data suggests that although RT-PCR tests perform better than antigen tests in detecting infected individuals and preventing transmission, more frequent antigen testing, e.g., every day or every 3 days, is comparable to less frequent RT-PCR tests, at the expense of many more false-negative tests. This indicates that frequent antigen tests, potentially self-administered at home could be an important tool in combating spread of infection.4

                  The Talis One delivers all the benefits of molecular tests with similar speed and convenience of antigen tests

                  As can be seen from the above discussion, the antigen vs. molecular test debate has primarily been one of test quality versus speed, with the molecular test being used as the gold standard, although it can take days to get results, and the antigen test being used when speed is more important than sensitivity.

                  However, the Talis One is set to change the cost/benefit balance in this debate. It’s a molecular test that can be done quickly and easily at the point-of-care, delivering results in under 30 minutes. And unlike other point-of-care tests, the Talis One’s unique cartridge technology includes solid-phase nucleic acid extraction, which gives it a sensitivity and LOD that’s comparable to molecular tests performed in a lab, enabling excellence at the point of care.

                  Conclusion

                  In the antigen vs. molecular test debate, the best test is the one that gives you the highest sensitivity and specificity in the shortest amount of time. Molecular testing is the gold standard, although antigen testing can be effective when speed is necessary. Now, with the Talis One, you can get similar speed and point-of-care convenience as an antigen test with the quality you could previously only get from a central lab molecular test.

                       

                  Related Articles

                  Article
                  July 18, 2022

                  Summer Travel 2022 – We’re Still in a Pandemic

                  In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
                  Article
                  June 15, 2022

                  Sexually Transmitted Infections and Disease: the Silent Pandemic

                  Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
                  Article
                  May 13, 2022

                  COVID-19: It’s Not Over Yet

                  It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
                  Article
                  March 16, 2022

                  COVID-19 Testing for Travel—What Your Patients Need to Know

                  Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

                  Join Our Newsletter

                  Subscribe to our newsletter for information about our products and company updates.


                    TALIS BIOMEDICAL

                    The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

                    © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

                    *Additional testing solutions are currently in development and not available for sale.

                    References

                    1. Antigen and Molecular Tests for COVID-19. COVID-19 Testing Toolkit website. Accessed July 9, 2021. https://www.centerforhealthsecurity.org/covid-19TestingToolkit/molecular-based-tests/current-molecular-and-antigen-tests.html#Current-Molecular-Tests
                    2. Hanson KE, et al. IDSA Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Clin Infect Dis. 2020 Jun 16;ciaa760. doi: 10.1093/cid/ciaa760.
                    3. Hanson KE, et al. IDSA Guidelines on the Diagnosis of COVID-19: Antigen Testing. Clin Infect Dis. 2021 Jun 23;ciab557. doi: 10.1093/cid/ciab557.
                    4. Ke R, et al. In vivo kinetics of SARS-CoV-2 infection and its relationship with a person’s infectiousness. medRxiv. Preprint. 2021 Jun 30. doi: 10.1101/2021.06.26.21259581. Accessed July 10, 2021.

                    SARS-COV-2 Variants and Their Impact on Molecular Tests

                         

                    As new variants of SARS-CoV-2 arise, they can impact diagnostic testing, potentially resulting in false negative results. To confidently make treatment decisions, achieve best-possible patient outcomes, and drive operational and clinical efficiency in a point-of-care setting, you need highly sensitive, rapid molecular tests capable of detecting all existing and emerging SARS-CoV-2 variants.

                    Which SARS-CoV-2 Tests Are Susceptible to False Negatives?

                    Molecular tests are straightforward to design for pathogen detection because they are largely based on an RNA sequence. However, viruses that rapidly evolve, such as SARS-CoV-2, can influence test sensitivity based on the sequence of the variant, the design of the test and the prevalence of the variant in the population.

                    Earlier this year, the FDA identified four EUA-authorized molecular tests that could be impacted by SARS-CoV-2 genetic variants, such as the B.1.1.7 variant that has been associated with an increased risk of transmission.1-2

                    It is important to be aware that genetic variants are expected to continue to emerge in SARS-CoV-2, which can threaten the sensitivity of virtually any molecular test. This is due to the possibility that one of the targets is driving the sensitivity, so that even if the others still match perfectly the sensitivity can be reduced based on a mutation in a single target. By choosing a test that uses multiple genetic targets, a test will be less likely to be impacted by increased prevalence of genetic variants.3

                    How To Know If SARS-CoV-2 Variants Impact Your Molecular Test?


                    Consider the patterns of detection
                    for your specific test. By choosing a test that uses multiple genetic targets, unfamiliar patterns may reveal the presence of new variants without impacting the final result of your test.

                    Stay up-to-date on emerging SARS-CoV-2 variants4, and their ability to evade detection by specific viral diagnostic tests.

                    Perform a repeat test. Per FDA recommendations5, consider negative results in combination with clinical observations, patient history and epidemiological information and repeat testing with a different test targeting different genetic regions if COVID-19 is still suspected.

                    How Do SARS-CoV-2 Molecular Tests Perform at the Point-of-Care?


                    All molecular tests used at the point-of-care are significantly faster than central-lab molecular tests 

                    Compared with central lab molecular tests, which may take up to several days, many point-of-care (POC) molecular test results are generated in up to 45 minutes6.

                    Point-of-care molecular tests integrated with nucleic acid extraction are more sensitive than those without this crucial sample preparation step

                    Not all POC molecular tests are created equal. There are some that incorporate nucleic acid extraction (e.g., Talis One) and many that do not, and this feature appears to influence the sensitivity of the test.7 Tests integrated with nucleic acid extraction can deliver significantly lower limits of detection (LoD)—with Talis One sensitivity approaching the range of lab-quality tests.7 Confirmatory testing for presumptive negatives may not be required.

                    Talis One provides rapid and accurate SARS-CoV-2 detection—quickly delivering central lab-quality results at the point of care

                    At Talis, we strive to use the best technology to bring the precision of lab-based molecular testing to the point-of-care. The Talis One Covid-19 Test System is designed to detect the ORF1ab and N gene (highly conserved regions) to remain sensitive in the presence of new variants and minimize the need for repeat testing. By integrating solid-phase extraction with innovative nucleic acid amplification technology, the Talis One COVID-19 Test System provides a sample-to-answer POC test where clear, actionable, highly sensitive results are generated in less than 30 minutes—helping healthcare providers enhance patient experience and patient outcomes.

                    Confidently determine who needs to quarantine and be treated to achieve better patient outcomes with the Talis One COVID-19 Test. 

                    Talis One COVID-19 Test System

                    Central lab-quality SARS-CoV-2 molecular testing for a variety of care settings—less than 30 minutes from sample to results.

                    Learn More
                         

                    Related Articles

                    Article
                    July 18, 2022

                    Summer Travel 2022 – We’re Still in a Pandemic

                    In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
                    Article
                    June 15, 2022

                    Sexually Transmitted Infections and Disease: the Silent Pandemic

                    Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
                    Article
                    May 13, 2022

                    COVID-19: It’s Not Over Yet

                    It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
                    Article
                    March 16, 2022

                    COVID-19 Testing for Travel—What Your Patients Need to Know

                    Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

                    Join Our Newsletter

                    Subscribe to our newsletter for information about our products and company updates.


                      TALIS BIOMEDICAL

                      The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

                      © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

                      *Additional testing solutions are currently in development and not available for sale.

                      References

                      1. SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests. U.S. Food and Drug Administration website. Updated June 3, 2021. Accessed June 25, 2021. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests
                      2. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States. Centers for Disease Control and Prevention website. Updated January 22, 2021. Accessed June 25, 2021.https://www.cdc.gov/mmwr/volumes/70/wr/mm7003e2.htm
                      3. SARS-CoV-2 E Gene Variant Alters Analytical Sensitivity Characteristics of Viral Detection Using a Commercial Reverse Transcription-PCR Assay https://journals.asm.org/doi/full/10.1128/JCM.00075-21 Accessed August 12, 2021
                      4. Genetic Variants of SARS-CoV-2 May Lead to False Negative. U.S. Food and Drug Administration website. Updated March 30, 2021. Accessed June 25, 2021. https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2
                      5. Science Brief: Emerging SARS-CoV-2 Variants. Centers for Disease Control and Prevention website. Updated January 28, 2021. Accessed June 25, 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html
                      6. Manufacturers’ instructions for use accessed August 12, 2021 at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular
                      7. Subsoontorn, P., Lohitnavy, M. & Kongkaew, C. The diagnostic accuracy of isothermal nucleic acid point-of-care tests for human coronaviruses: A systematic review and meta-analysis. Sci Rep 10, 22349 (2020). https://doi.org/10.1038/s41598-020-79237-7 Accessed August 12, 2021